Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced b

Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer
J Dose-Schwarz, R Tiling, S Avril-Sassen, S Mahner, A Lebeau, C Weber, M Schwaiger, F Jänicke, M Untch and N Avril
Br J Cancer 2010 102: 35-41

Link to Journal

FDG-PET does not provide an accurate assessment of residual tumour after primary chemotherapy of breast cancer. Magnetic resonance imaging offers the highest sensitivity, but all imaging modalities have distinct limitations in the assessment of residual tumour tissue when compared with histopathology

Using MRI to plan breast-conserving surgery following neoadjuvant chemotherapy for early breast cancer

M Bhattacharyya, D Ryan, R Carpenter, S Vinnicombe & C J Gallagher
British Journal of Cancer (2008) 98, 289-293
http://www.nature.com/bjc/journal/v98/n2/full/6604171a.html

Contrast-enhanced magnetic resonance imaging (MRI) was used to monitor the response of patients undergoing neoadjuvant chemotherapy for breast cancer with the aim of undergoing breast-conserving surgery (BCS). Magnetic resonance imaging appears to be superior to conventional methods for assessing pathological response and the low rate of re-operation for positive margins indicates a valuable role in aiding the decision to undergo BCS or mastectomy.